carbostyril has been researched along with Colitis, Granulomatous in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allocca, M; Correale, C; Danese, S; Fiorino, G; Furfaro, F; Gabbiadini, R; Gilardi, D; Peyrin-Biroulet, L; Zilli, A | 1 |
| Bruns, T; Büning, J; Fichtner-Feigl, S; Kruis, W; Maaser, C; Preiß, JC; Reuken, PA; Schmelz, R; Stallmach, A; Teich, N | 1 |
| Jick, S; Troelsen, FS | 1 |
| Barkay, H; Brown, K; Colombel, JF; D'Haens, G; Feagan, BG; Haviv, A; Rutgeerts, P; Sakov, A; Sandborn, WJ | 1 |
| Dong, J; Gong, J; Li, J; Li, Y; Shen, X; Sun, J; Wang, H; Zhao, J; Zhu, W; Zuo, L | 1 |
| Danese, S; Olivera, P; Peyrin-Biroulet, L | 1 |
| D'Haens, G; Löwenberg, M | 1 |
| Zhang, TM | 1 |
3 review(s) available for carbostyril and Colitis, Granulomatous
| Article | Year |
|---|---|
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD.
Topics: Acetates; Animals; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Heterocyclic Compounds, 3-Ring; Humans; Indans; Indoles; Janus Kinase Inhibitors; Oxadiazoles; Piperidines; Pyridines; Pyrimidines; Quinolones; Sphingosine-1-Phosphate Receptors; Triazoles | 2020 |
Novel targets for inflammatory bowel disease therapeutics.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Adhesion Molecules; Certolizumab Pegol; Colitis, Ulcerative; Crohn Disease; Humans; Immunoglobulin Fab Fragments; Infliximab; Natalizumab; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Tumor Necrosis Factor-alpha; Ustekinumab | 2013 |
[Advances in research on atypical mycobacterium infections].
Topics: Crohn Disease; Humans; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Quinolones | 1988 |
1 trial(s) available for carbostyril and Colitis, Granulomatous
| Article | Year |
|---|---|
A phase II study of laquinimod in Crohn's disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Crohn Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Quinolones; Treatment Outcome; Young Adult | 2015 |
4 other study(ies) available for carbostyril and Colitis, Granulomatous
| Article | Year |
|---|---|
Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry.
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Antifungal Agents; beta-Lactamase Inhibitors; Candida albicans; Carbapenems; Cephalosporins; Crohn Disease; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterococcus; Female; Germany; Humans; Immunosuppressive Agents; Intestinal Perforation; Length of Stay; Levofloxacin; Male; Penicillins; Prospective Studies; Quinolones; Registries; Streptococcus; Young Adult | 2018 |
Antibiotic Use in Childhood and Adolescence and Risk of Inflammatory Bowel Disease: A Case-Control Study in the UK Clinical Practice Research Datalink.
Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Case-Control Studies; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Female; Humans; Logistic Models; Male; Metronidazole; Quinolones; Risk Factors; United Kingdom; Young Adult | 2020 |
Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function.
Topics: Animals; Colitis; Crohn Disease; Cytokines; Interleukin-10; Intestinal Mucosa; Leukocyte Common Antigens; Lymphocyte Count; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Permeability; Quinolones | 2015 |
Next generation of small molecules in inflammatory bowel disease.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Indans; Inflammatory Bowel Diseases; Oxadiazoles; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |